Safety and acceptability of penile application of 2 candidate topical microbicides: BufferGel and PRO 2000 Gel. 3 Randomized trials in healthy low-risk men and HIV-positive men

Journal of Acquired Immune Deficiency Syndromes

Volumn 33, Issue 4, 2003, Pages 476-483

  Tabet, Stephen R ^a   Callahan, Marianne M ^b   Mauck, Christine K ^b   Gai, Fang ^c   Coletti, Anne S ^d   Profy, Albert T ^e   Moench, Thomas R ^f   Soto Torres, Lydia E ^g   Poindexter III, Alfred N ^h   Frezieres, Ron G ⁱ   Walsh, Terri L ⁱ   Kelly, Clifton W ^c   Richardson, Barbra A ^a   Van Damme, Lut ^b   Celum, Constance L ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Contraceptive Res/Devmt Program ^*  (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d FAMILY HEALTH INTERNATIONAL   (United States)

^e Indevus Pharmaceuticals Inc   (United States)

^f REPROTECT INC   (United States)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^h BAYLOR COLLEGE OF MEDICINE   (United States)

ⁱ California Family Health Council Inc   (United States)

Author keywords

Acceptability; BufferGel; HIV; Male safety; Microbicide; Prevention; PRO 2000 Gel

Indexed keywords

ANTIBIOTIC AGENT; BENZOIC ACID; BUFFER GEL; CARBOMER; DIBASIC POTASSIUM PHOSPHATE; DISODIUM HYDROGEN PHOSPHATE; EDETATE DISODIUM; K Y JELLY; LACTIC ACID; MAGNESIUM SULFATE; METHYL PARABEN; NAPHTHALENESULFONATE POLYMER; NONOXINOL; PETROLATUM; PLACEBO; PRO 2000 GEL; PROPYL PARABEN; SODIUM DIHYDROGEN PHOSPHATE; SORBIC ACID; TRIETHANOLAMINE SALICYLATE; UNCLASSIFIED DRUG;

ABRASION; ADULT; ANTIMICROBIAL ACTIVITY; ARTICLE; BALANITIS; BURNING SENSATION; CANDIDIASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; GEL; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACERATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SEXUALLY TRANSMITTED DISEASE; SKIN DISCOLORATION; SKIN IRRITATION; SKIN TINGLING;

EID: 0038298321     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200308010-00008     Document Type: Article

References (29)

1. Joint United Nations Programme on AIDS. AIDS epidemic update: December, 2001. Geneva, Switzerland: UNAIDS; 2001.
2. Centers for Disease Control and Prevention. Update: barrier protection against HIV infection and other sexually transmitted diseases. MMWR Morb Mortal Wkly Rep. 1993;42:589-591, 597.
3. Stein ZA. HIV prevention: the need for methods women can use. Am J Public Health. 1990;80:460-462.
4. Stone AB, Hitchcock PJ. Vaginal microbicides for preventing the sexual transmission of HIV. AIDS. 1994;8(suppl 1):S285-S293.
5. Elias CJ, Heise LL. Challenges for the development of female-controlled vaginal microbicides. AIDS. 1994;8:1-9.
6. Elias CJ, Coggins C. Female-controlled methods to prevent sexual transmission of HIV. AIDS. 1996;10:S43-S51.
7. Eng TR, Butler WT, eds. The Hidden Epidemic: Confronting Sexually Transmitted Diseases. Washington, DC: National Academy Press; 1997.
8. Niruthisard S, Roddy RE, Chutivongse S. The effects of frequent nonoxynol-9 use on the vaginal and cervical mucosa. Sex Transm Dis. 1991;18:176-179.
9. Kreiss J, Ngugi E, Holmes KK, et al. Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. JAMA. 1992;268:477-482.
10. Roddy RE, Cordero M, Cordero C, et al. A dosing study of nonoxynol-9 and genital irritation. Int J STD AIDS. 1993;4:165-170.
11. International Working Group on Vaginal Microbicides. Recommendations for the development of vaginal microbicides. AIDS. 1996;10:1-6.
12. Roddy RE, Zekeng L, Ryan KA, et al. A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. N Engl J Med. 1998;339:504-510.
13. Van Damme L, Ramjee G, Alary M, et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet. 2002;360:971-977.
14. World Health Organization. Technical Consultation on Nonoxynol-9. Summary Report of a WHO/CONRAD Workshop (Geneva, 9-10 October 2001). Geneva, Switzerland: World Health Organization; 2002.
15. Khanna KV, Whaley KJ, Zeitlin L, et al. Vaginal transmission of cell-associated HIV-1 in the mouse is blocked by a topical, membrane-modifying agent. J Clin Invest. 2002;109:205-211.
16. Zeitlin L, Hoen TE, Achilles SL, et al. Tests of Buffergel for contraception and prevention of sexually transmitted diseases in animal models. Sex Transm Dis. 2001;28:417-423.
17. Rusconi S, Moonis M, Merrill DP, et al. Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities. Antimicrob Agents Chemother. 1996;40:234-236.
18. Greenhead P, Hayes P, Watts PS, et al. Parameters of human immunodeficiency virus infection of human cervical tissue and inhibition by vaginal virucides. J Virol. 2000;74:5577-5586.
19. Profy AT, Sonderfan AJ, Bourne N, et al. PRO 2000 gel, a potential topical microbicide for HIV prevention, can block infection by other sexually transmitted disease pathogens [abstract 33146]. In: Proceedings of the 12th World AIDS Conference; June 28-July 3, 1998; Geneva, Switzerland.
20. Weber J, Nunn A, O'Connor T, et al. "Chemical condoms" for the prevention of HIV infection: evaluation of novel agents against SHIV(89.6PD) in vitro and in vivo. AIDS. 2001;15:1563-1568.
21. Lewis MG, Wagner W, Yalley-Ogunro J, et al. Efficacy of PRO 2000 Gel in a macaque model for vaginal HIV transmission [abstract A-191]. In: Program and abstracts of Microbicides 2002; May 5-9, 2002; Antwerp, Belgium.
22. Bourne N, Bernstein DI, Ireland J, et al. The topical microbicide PRO 2000 protects against genital herpes infection in a mouse model. J Infect Dis. 1999;180:203-205.
23. Mayer KH, Peipert J, Fleming TR, et al. Safety and tolerability of BufferGel, a novel vaginal microbicide, in women in the United States. Clin Infect Dis. 2001;32:476-482.
24. van de Wijgert J, Fullem A, Kelly C, et al. Phase 1 trial of the topical microbicide BufferGel: safety results from four international sites. J Acquir Immune Defic Syndr. 2001;26:21-27.
25. Van Damme L, Wright A, Depraetere K, et al. A phase I study of a novel potential intravaginal microbicide, PRO 2000, in healthy sexually inactive women. Sex Transm Infect. 2000;76:126-130.
26. Mayer KH, Karim SA, Kelly C, et al. Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women. AIDS. 2003;17:321-329.
27. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000;342:921-929.
28. Coldiron BM, Bergstresser PR. Prevalence and clinical spectrum of skin disease in patients infected with human immunodeficiency virus. Arch Dermatol. 1989;125:357-361.
29. Valle SL. Dermatologic findings related to human immunodeficiency virus infection in high-risk individuals. J Am Acad Dermatol. 1987;17:951-961.